Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:activities |
broad spectrum
inhibits bacterial cell wall synthesis |
| gptkbp:appointed_by |
oral tablet
oral suspension |
| gptkbp:approves |
gptkb:1981
gptkb:FDA |
| gptkbp:brand |
Augmentin Duo
Augmentin ES Augmentin XR |
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:contains |
gptkb:amoxicillin
clavulanate potassium |
| gptkbp:contraindication |
penicillin allergy
|
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:dosage_form |
250 mg/62.5 mg
500 mg/125 mg 875 mg/125 mg |
| gptkbp:duration |
7 to 14 days
|
| gptkbp:formulation |
gptkb:tablet
suspension chewable tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
Augmentin
|
| gptkbp:interacts_with |
gptkb:methotrexate
gptkb:warfarin probenecid |
| gptkbp:is_available_in |
tablets
suspensions injectable form |
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_effective_against |
fungal infections
viral infections mycobacterial infections |
| gptkbp:is_used_for |
bacterial infections
|
| gptkbp:marketed_as |
various brand names
|
| gptkbp:requires |
gptkb:theorem
|
| gptkbp:side_effect |
nausea
diarrhea rash anaphylaxis thrombocytopenia hepatotoxicity eosinophilia superinfection |
| gptkbp:storage |
room temperature
away from moisture |
| gptkbp:suitable_for |
severe liver disease
severe renal impairment lactation pregnancy category B |
| gptkbp:used_in |
gptkb:healthcare_organization
sinusitis skin infections otitis media urinary tract infections |